Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to reduce adverse self-medication practices in older adults with hypertension.
| Condition | Intervention |
|---|---|
|
Cardiovascular Diseases Heart Diseases Hypertension |
Behavioral: Personal Education Program - Next Generation (PEP-NG) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension |
- Behaviors associated with potential drug interactions [ Time Frame: Measured at 0, 4, 8, 12 weeks ] [ Designated as safety issue: Yes ]
- Blood pressure readings [ Time Frame: Measured at weeks 0, 4, 8 and 12 ] [ Designated as safety issue: Yes ]
- Self-efficacy for avoiding adverse self-medication behaviors [ Time Frame: Measured at 0, 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
- Prescription medication adherence [ Time Frame: Measured at 0, 4, 8, 12 weeks ] [ Designated as safety issue: No ]
- Satisfaction with the PEP-NG [ Time Frame: Measured at 12 weeks ] [ Designated as safety issue: No ]
- Satisfaction with the APRN provider relationship [ Time Frame: Measured at 0, 4, 8, 12 weeks ] [ Designated as safety issue: No ]
- Healthcare utilization [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
- For APRNS: Knowledge of behaviors associated with adverse self-medication [ Time Frame: Measured pre-, post-training and 3 and 6 months ] [ Designated as safety issue: No ]
- For APRNS: Self-efficacy for communicating with older adults [ Time Frame: Measured pre-post training and 3 and 6 months ] [ Designated as safety issue: No ]
- For APRNS: Satisfaction with using the PEP-NG [ Time Frame: Measured at 6 months ] [ Designated as safety issue: No ]
- Knowledge for avoiding adverse self-medication behaviors [ Time Frame: Measured at 0, 4, 8, 12 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 240 |
| Study Start Date: | September 2005 |
| Estimated Study Completion Date: | July 2010 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Education
PEP education intervention
|
Behavioral: Personal Education Program - Next Generation (PEP-NG)
Adults aged 60 and over with hypertension will be randomized to usual care and intervention groups. Both groups will enter medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The intervention group will receive a tailored education program.
|
Detailed Description:
BACKGROUND:
Failure of older adults to take medications properly is estimated to be a factor in more than a quarter of emergency room visits and 10 percent of nursing home admissions, with a total cost of over $25 billion annually. It has been estimated that 10 percent of adverse drug events may be attributed to communication failure between the provider and patient. Lack of adherence to prescription medication protocols and adverse self-medication practices can result in drug interactions that can be fatal. In a health environment that promotes polypharmacy for older adults, a group that is less well able to see, hear, and understand medical information than the general population, a need exists to educate both older adults and their providers about the dangers of adverse drug interactions arising from self-medication.
DESIGN NARRATIVE:
The goal is to reduce adverse self-medication practices in older adults with hypertension. A computer program developed for older adults (Personal Education Program or PEP) will be modified as the next generation PEP, or PEP-NG, to include an interface to allow clients to enter self-medication behavior data independently on a wireless, touch screen tablet PC. Data entered on the PEP-NG will be analyzed via a secure server (ProHealth) and program content tailored to the specific adverse self-medication behaviors will be delivered. Summaries of the reported behaviors with corrective strategies will be printed for both patient and provider so the advanced practice registered nurse (APRN) has a good idea of the client's self-medication practices before beginning the face-to-face interview. Thus, the PEP-NG will make optimal use of the client's waiting time and the APRN's clinical time.
Specific aims are at three levels. 1) To design an interface for the PEP-NG with: a) desirable characteristics for both older adults and primary care providers; and b) minimal user burden. 2) To show that APRNs will increase: a) knowledge concerning potential drug interactions arising from older adults' self-medication practices; b) self-efficacy for teaching older adults about potential drug interactions; c) self-efficacy for communicating with older adults about self-medication; and to d) demonstrate satisfaction using the PEP-NG with clients. 3) To show that older adults using the PEP-NG will: a) increase knowledge concerning potential drug interactions arising from self-medication practices; b) increase self-efficacy as to how to avoid potential drug interactions arising from self-medication practice; c) reduce self-reported adverse behaviors associated with potential drug interactions; 4) improve prescription medication adherence; d) achieve target blood pressure readings; and demonstrate e) satisfaction with the PEP-NG and f) the APRN provider relationship. User-sensitive inclusive design methods will be used to develop and test the patient data interface. After beta-testing the PEP-NG in the primary care laboratory, the PEP-NG will be piloted by 10 APRNs affiliated with ProHealth primary care practices. RMANOVA with one within subjects factor (TIME) will be performed on APRNs' outcome measures at time 0, immediate post-instruction, and 3 and 6 months later. APRNs will each recruit 24 clients (240 total) meeting study criteria. The PEP-NG software will randomly assign each APRN's clients to either control (data collection only) and experimental (data collection plus educational intervention with targeted messages). Client outcome will be assessed at 0, 4, 8, 12, and 52 weeks and analyzed as a mixed ANOVA with NURSE and GROUP as between-subjects factors and TIME as a repeated-measures factor. Healthcare utilization will be compared between the 2 groups after 52 weeks and a cost-benefit analysis conducted.
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria for Older Adults:
- Older adult diagnosed with hypertension
- Health literacy score (REALM) of 44 or greater
- Independent physical and cognitive functioning
- Visual acuity of at least 20/100, with corrective lenses
Inclusion Criteria for APRNs:
- Affiliated with ProHealth Physicians, Inc. practice site in CT and/or
- Affiliated with APRNet practice sites in CT
Contacts and Locations| United States, Connecticut | |
| University of Connecticut | Recruiting |
| Storrs, Connecticut, United States, 06269 | |
| Contact: Patricia J. Neafsey, RD, PhD 860-486-0505 Patricia.neafsey@uconn.edu | |
| Principal Investigator: Patricia J. Neafsey, RD, PhD | |
| Principal Investigator: | Patricia J. Neafsey, RD, PhD | University of Connecticut |
More Information
No publications provided
| Responsible Party: | Patricia J. Neafsey, PhD, University of Connecticut |
| ClinicalTrials.gov Identifier: | NCT00201201 History of Changes |
| Other Study ID Numbers: | 282, R01 HL84208 |
| Study First Received: | September 16, 2005 |
| Last Updated: | July 10, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
|
Older Adults Primary Care Hypertension Adherence |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013